AA
DRMA icon

Advisory Alpha’s Dermata Therapeutics DRMA Stock Holding History

Advisory Alpha’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9K Buy
+10,000
New +$12.6K ﹤0.01% 571

Other funds holding DRMA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.8B AUM 19.11% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Advisory Alpha's DRMA Position: Q2 2026 in Review

Advisory Alpha opened a new position in Dermata Therapeutics (DRMA) in Q2 2026: 10,000 shares worth $12.9K. The stake represents ﹤0.01% of the portfolio and ranks #571 among its holdings.

13 funds tracked by Wall St. Rank hold DRMA as of Q2 2026.

  • Advisory Alpha held 10,000 shares of Dermata Therapeutics worth $12.9K as of Q2 2026.
  • Dermata Therapeutics was a new Advisory Alpha position in Q2 2026.
  • Dermata Therapeutics made up ﹤0.01% of Advisory Alpha's portfolio in Q2 2026, its #571 holding.
  • 13 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q2 2026.

Based on Advisory Alpha's 13F filing for Q2 2026, filed 11 Aug 2026.